Paradigm Biocapital Advisors LP Arvinas, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.47 Billion
- Q2 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Arvinas, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,438,149 shares of ARVN stock, worth $67 Million. This represents 2.63% of its overall portfolio holdings.
Number of Shares
2,438,149
Previous 2,614,935
6.76%
Holding current value
$67 Million
Previous $108 Million
39.87%
% of portfolio
2.63%
Previous 4.05%
Shares
8 transactions
Others Institutions Holding ARVN
# of Institutions
221Shares Held
68.8MCall Options Held
166KPut Options Held
31.3K-
Eco R1 Capital, LLC San Francisco, CA6.73MShares$185 Million6.33% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.67MShares$183 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$172 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.99MShares$110 Million0.01% of portfolio
-
Avidity Partners Management LP Dallas, TX2.99MShares$82.2 Million3.91% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $1.46B
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...